The Lipitor Warning for GLP-1 Drugmakers

Pfizer’s Lipitor experience shows the structural risks that today’s GLP-1 innovators may soon face

1

GLP-1 obesity drugs are compared to Lipitor, sharing similarities in commercial profiles and structural risks.
2

Lipitor's success in Norway was hindered by parallel imports, which accounted for 90% of the atorvastatin market during its patent period.
3

Norway's pharmacy market is dominated by three chains that prefer parallel imports for higher financial margins.
4

Price differentials within the European Economic Area create arbitrage opportunities, impacting pharmaceutical sales.
5

The legal framework in the EEA allows for the free movement of goods, complicating manufacturers' control over pricing.

1